


IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Previously Presented): A compound of formula (I):



wherein

R¹ is a 4-(lower) alkyl-imidazol-1-yl or a 4,5-di(lower) alkyl-imidazol-1-yl group,

R² is a hydrogen atom or a lower alkyl group, and

R³ is a fluorenyl group,

or pharmaceutically acceptable salts thereof.

Claim 2 (Canceled).

Claim 3 (Previously Presented): A pharmaceutical composition, which has 5-HT antagonism activity, comprising a compound of claim 1 or its non-toxic pharmaceutically acceptable salt together with pharmaceutical carrier.

Claim 4 (Previously Presented): The compound of formula (I) of claim 1, wherein the compound is in the form of a pharmaceutically acceptable salt.

Claim 5 (Previously Presented): The compound of formula (I) of claim 4, wherein the compound is in the form of a salt of an inorganic base, a salt of an organic base, an inorganic addition salt, an organic carboxylic or sulfonic salt, a salt of a basic or acidic amino acid, or mixtures thereof.

Claim 6 (Previously Presented): The compound of formula (I) of claim 5, wherein the compound is in the form of a salt of an alkali metal or a salt of an alkaline earth metal.

Claim 7 (Previously Presented): The compound of formula (I) of claim 5, wherein the compound is in the form of a triethylamine salt, a pyridine salt, a picoline salt, an ethanolamine salt, a triethanolamine salt, a dicyclohexylamine salt, or an N,N'-dibenzylethylenediamine salt.

Claim 8 (Previously Presented): The compound of formula (I) of claim 5, wherein the compound is in the form of a hydrochloride salt, a hydrobromide salt, a hydriodide salt, a sulfate salt, or a phosphate salt.

Claim 9 (Previously Presented): The compound of formula (I) of claim 5, wherein the compound is in the form of a formate salt, an acetate salt, a trifluoroacetate salt, a maleate salt, a tartrate salt, a methanesulfonate salt, a benzenesulfonate salt, or a p-toluenesulfonate salt.

Claim 10 (Previously Presented): The compound of formula (I) of claim 5, wherein the compound is in the form of an arginine salt, an aspartate salt, or a glutamate salt.

Claim 11 (Previously Presented): The compound of formula (I) of claim 1, wherein R¹ is a lower alkyl group having 1 to 6 carbon atoms.

Claim 12 (Previously Presented): The compound of formula (I) of claim 1, wherein R^1 is a lower alkyl group having 1 to 4 carbon atoms.

Claim 13 (Previously Presented): The compound of formula (I) of claim 1, wherein R^1 is a lower alkyl group selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, t-butyl, pentyl and hexyl.

Claim 14 (Previously Presented): The pharmaceutical composition of claim 3, wherein the pharmaceutical composition is in the form of a tablet, granule, powder, capsule, solution, suspension, syrup, emulsion or lemonade.

Claim 15 (Canceled).

Claim 16 (Previously Presented): The pharmaceutical composition of claim 3, wherein the amount of the compound of formula (I) is 0.05 to 100 mg.